These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 17406798)

  • 1. Organ-sparing treatment of advanced bladder cancer: paclitaxel as a radiosensitizer.
    Müller AC; Diestelhorst A; Kuhnt T; Kühn R; Fornara P; Scholz HJ; Dunst J; Zietman AL
    Strahlenther Onkol; 2007 Apr; 183(4):177-83. PubMed ID: 17406798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organ-sparing treatment in muscle-invasive bladder cancer.
    Dunst J; Diestelhorst A; Kühn R; Müller AC; Scholz HJ; Fornara P
    Strahlenther Onkol; 2005 Oct; 181(10):632-7. PubMed ID: 16220401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.
    Kaufman DS; Winter KA; Shipley WU; Heney NM; Wallace HJ; Toonkel LM; Zietman AL; Tanguay S; Sandler HM
    Urology; 2009 Apr; 73(4):833-7. PubMed ID: 19100600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.
    Danesi DT; Arcangeli G; Cruciani E; Altavista P; Mecozzi A; Saracino B; Orefici F
    Cancer; 2004 Dec; 101(11):2540-8. PubMed ID: 15481058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer.
    Lin CC; Hsu CH; Cheng JC; Huang CY; Tsai YC; Hsu FM; Huang KH; Cheng AL; Pu YS
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):442-8. PubMed ID: 19307067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group.
    Gogna NK; Matthews JH; Turner SL; Mameghan H; Duchesne GM; Spry N; Berry MP; Keller J; Tripcony L;
    Radiother Oncol; 2006 Oct; 81(1):9-17. PubMed ID: 17011058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer.
    Weiss C; Engehausen DG; Krause FS; Papadopoulos T; Dunst J; Sauer R; Rödel C
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1072-80. PubMed ID: 17467193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome of chemoradiotherapy for T1G3 bladder cancer.
    Inoue M; Ishioka J; Fukuda H; Kageyama Y; Saito Y; Higashi Y
    Int J Urol; 2008 Aug; 15(8):747-50. PubMed ID: 18786198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long term follow-up of combined radiochemotherapy for locally advanced bladder carcinoma.
    Retz M; Lehmann J; Trocha C; Loch T; Seppelt U; Fischer C; Pinkenburg FA; Timm KJ; Wellek S; Stöckle M
    Cancer; 2000 Sep; 89(5):1089-94. PubMed ID: 10964339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiochemotherapy after transurethral resection is an effective treatment method in T1G3 bladder cancer.
    Akçetin Z; Todorov J; Tüzel E; Engehausen DG; Krause FS; Sauer R; Schrott KM; Rödel C
    Anticancer Res; 2005; 25(3A):1623-8. PubMed ID: 16033071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience.
    Perdonà S; Autorino R; Damiano R; De Sio M; Morrica B; Gallo L; Silvestro G; Farella A; De Placido S; Di Lorenzo G
    Cancer; 2008 Jan; 112(1):75-83. PubMed ID: 18008364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total cystectomy versus bladder preservation therapy for locally invasive bladder cancer: effect of combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation.
    Azuma H; Yamamoto K; Inamoto T; Ibuki N; Kotake Y; Sakamoto T; Kiyama S; Ubai T; Takahara K; Segawa N; Narumi Y; Katsuoka Y
    Am J Clin Oncol; 2009 Dec; 32(6):592-606. PubMed ID: 19593084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy.
    Hata M; Miyanaga N; Tokuuye K; Saida Y; Ohara K; Sugahara S; Kagei K; Igaki H; Hashimoto T; Hattori K; Shimazui T; Akaza H; Akine Y
    Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1371-9. PubMed ID: 16580495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose chemoradiotherapy followed by partial or radical cystectomy against muscle-invasive bladder cancer: an intent-to-treat survival analysis.
    Koga F; Yoshida S; Kawakami S; Kageyama Y; Yokoyama M; Saito K; Fujii Y; Kobayashi T; Kihara K
    Urology; 2008 Aug; 72(2):384-8. PubMed ID: 18455771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?
    Weiss C; Wolze C; Engehausen DG; Ott OJ; Krause FS; Schrott KM; Dunst J; Sauer R; Rödel C
    J Clin Oncol; 2006 May; 24(15):2318-24. PubMed ID: 16710030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of two-port and four-port irradiation in the bladder preservation therapy for locally invasive bladder cancer.
    Sawada Y; Takeuchi Y; Iwasawa T; Kuroda K; Matsushima M; Nagamoto M; Wakayama M
    Int J Urol; 2006 Dec; 13(12):1470-4. PubMed ID: 17118019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updated results of bladder-sparing trimodality approach for invasive bladder cancer.
    Zapatero A; Martin de Vidales C; Arellano R; Bocardo G; Pérez M; Ríos P
    Urol Oncol; 2010; 28(4):368-74. PubMed ID: 19362865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined-modality treatment and organ preservation in bladder cancer. Do molecular markers predict outcome?
    Weiss C; Rödel F; Wolf I; Papadopoulos T; Engehausen DG; Schrott KM; Sauer R; Rödel C
    Strahlenther Onkol; 2005 Apr; 181(4):213-22. PubMed ID: 15827690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
    BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Organ preservation for muscle-invasive bladder cancer by transurethral resection.
    Leibovici D; Kassouf W; Pisters LL; Pettaway CA; Wu X; Dinney CP; Grossman HB
    Urology; 2007 Sep; 70(3):473-6. PubMed ID: 17905099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.